All Stories

  1. Evolution of type 2 diabetes mellitus treatment approaches
  2. Discordance between HbA1c and glycemia
  3. Talks and tweets from the ADA
  4. Adherence and diabetes
  5. World congress on insulin resistance, diabetes and cardiovascular disease
  6. American College of Physicians diabetes guidelines attempt to turn back the clock, conflating good HbA1c with hypoglycemia
  7. Transition from hospital to outpatient diabetes care
  8. Diabetes and branched-chain amino acids: What is the link?
  9. The kidney and cardiovascular outcome trials
  10. How does CKD affect HbA1c?
  11. Metabolic memory: Evolving concepts
  12. Journal of Diabetes: Ushering in Volume 10
  13. American Society of Clinical Oncology Summit on Addressing Obesity Through Multidisciplinary Provider Collaboration: Key Findings and Recommendations for Action
  14. Response to Comment on Bloomgarden et al. Is HbA 1c <7% a Marker of Poor Performance in Individuals >65 Years Old? Diabetes Care 2017;40:526–528
  15. Beyond HbA1c
  16. Is insulin the preferred treatment for HbA1c >9%?
  17. Non-alcoholic fatty liver disease and type 2 diabetes: Importance of glycemic control
  18. Upper extremity arthropathy in diabetes
  19. Diabetes and tuberculosis: An important relationship
  20. Is HbA1c<7% a Marker of Poor Performance in Individuals >65 Years Old?
  21. Chelation for diabetes complications: A neglected approach?
  22. Diabetes treatment over age 65: Is worse control really better?
  23. The Journal of Diabetes in its ninth year
  24. Fear of hypoglycemia
  25. The Future of Diabetes
  26. Self-monitoring of blood glucose for type 2 diabetes
  27. The Future of Diabetes
  28. New approaches to wound healing for diabetes 促进糖尿病患者伤口愈合的新方法
  29. AACE/ACE COMPREHENSIVE DIABETES MANAGEMENT ALGORITHM 2015
  30. Determinants of adherence to diabetes treatment
  31. Sodium-glucose cotransporter 2 inhibitors and renal function钠-葡萄糖共转运体2抑制剂与肾功能
  32. Diabetes and cancer: Findings from the REACTION study 糖尿病与恶性肿瘤:来自REACTION研究的发现
  33. Advances in sleep research 睡眠的研究进展
  34. Helping people with diabetes to exercise 帮助糖尿病患者运动
  35. PO368 DISCONTINUATION AND ADHERENCE FOR SITAGLIPTIN VERSUS SULFONYLUREA AS ADD-ON TO METFORMIN
  36. Individualizing therapy: Do we have the tools to do it? 个体化治疗:我们有具体的执行方法吗?
  37. Afrezza: Some questions about a new approach to prandial insulin 关于一种新型餐时胰岛素的一些问题
  38. Is glycemic control a quinidine-like intervention? 控制血糖与使用奎尼丁治疗一样吗?
  39. Basal insulin or longacting GLP-1 receptor agonists—making the right choice
  40. Lessons from glargine trials: What is the goal fasting glucose with basal insulin? (来自甘精胰岛素临床试验的经验教训:使用基础胰岛素治疗的空腹血糖目标是什么?)
  41. Association is not causation, particularly with “adjustment” (相关性不是因果关系,特别是“校正过”的相关性)
  42. Metformin associated with better cardiovascular outcomes than other glycaemic therapies
  43. Role of glucagon in treating diabetes: Evidence and concepts (胰高血糖素在糖尿病治疗中的作用:证据与概念)
  44. Comment on: Selvin et al. No Racial Differences in the Association of Glycated Hemoglobin With Kidney Disease and Cardiovascular Outcomes. Diabetes Care 2013;36:2995-3001
  45. Cardiovascular safety trials: Be careful what you wish for (心血管安全性研究:当心你许的愿)
  46. Diabetes in China: Prevalence, diagnosis, and control (糖尿病在中国:流行、诊断与控制现状)
  47. Diabetes and aging (糖尿病与老龄化)
  48. Diabetes and Cancer—An AACE/ACE Consensus Statement
  49. Sodium glucose transporter 2 inhibition: A new approach to diabetes treatment (抑制钠葡萄糖转运体2:一种新的糖尿病治疗方法)
  50. Diabetes and cancer relationships (糖尿病与肿瘤的关联性)
  51. American Association of Clinical Endocrinologists' Comprehensive Diabetes Management Algorithm 2013 Consensus Statement
  52. The Journal of Diabetes : Continuing the dialogue (糖尿病杂志:继续进行对话)
  53. AACE Comprehensive Diabetes Management Algorithm 2013
  54. Sugar-sweetened beverages: Changing the tide (含糖饮料:潮流的改变)
  55. Screening children for diabetes: what can ‘low-tech’ accomplish?
  56. The Role of Bromocriptine-QR in the Management of Type 2 Diabetes Expert Panel Recommendations
  57. The Clinical Approach to the Detection of Lipodystrophy – An AACE Consensus Statement
  58. Diabetes treatment: The coming paradigm shift
  59. Current Issues in GLP-1 Receptor Agonist Therapy for Type 2 Diabetes
  60. Learning from ORIGIN
  61. How do we gauge the success of treatment of diabetes?
  62. Diabetes: East meets West. The Joint American Association of Clinical Endocrinologists-Chinese Society of Endocrinology (AACE-CSE) Symposium
  63. An evaluation of diabetes self-management applications for Android smartphones
  64. Diabetes: The prototypical non-communicable disease
  65. Is there a U-shaped curve of A1c versus mortality?
  66. Did AIM-HIGH aim too low?
  67. Hypoglycemia in Type 2 Diabetes: Current Controversies and Changing Practices
  68. Da Qing, Finnish DPP, Tripod, and Dream: Lifestyle and Thiazolidinediones in the Prevention of Diabetes
  69. Comprehensive diabetes cardiovascular treatment =  sugar + blood pressure + lipids
  70. Final "Perspectives on the News": American Association of Clinical Endocrinology and American Diabetes Association 2011
  71. American Diabetes Association Postgraduate Meetings--2011
  72. Congenitally Corrected Transposition of the Great Arteries with Anomalous Inferior Vena Cava Drainage: Multimodality Imaging
  73. World Congress on Insulin Resistance, Diabetes, and Cardiovascular Disease: Part 4
  74. World Congress on Insulin Resistance, Diabetes, and Cardiovascular Disease: Part 3
  75. Five Ms of adherence
  76. World Congress on Insulin Resistance, Diabetes, and Cardiovascular Disease
  77. World Congress on Insulin Resistance, Diabetes, and Cardiovascular Disease: Part 1
  78. Insulin Concerns and Promises
  79. Nonnutritive Sweeteners, Fructose, and Other Aspects of Diet
  80. Hypertension in Diabetes: Treatment Considerations
  81. Diabetes Treatment and Cardiovascular Safety
  82. Fibrate use in diabetes: New concepts
  83. Iron-deficiency anemia, non-iron-deficiency anemia and HbA1c among adults in the US*
  84. Diabetes and Cardiovascular Disease
  85. Type 2 Diabetes: Uses of thiazolidinediones and insulin
  86. The American Diabetes Association's 57th Annual Advanced Postgraduate Course: Diabetes risk, vitamin D, polycystic ovary syndrome, and obstructive sleep apnea
  87. Bariatric Surgery, Exercise, and Inpatient Glycemia Treatment: The American Diabetes Association's 57th Annual Advanced Postgraduate Course
  88. Liraglutide and calcitonin
  89. The Avandia debate: An unhappy conclusion
  90. Cardiovascular Disease and Glycemic Treatment
  91. World Congress on the Insulin Resistance Syndrome, 2009: The kidney, the liver, and insulin resistance
  92. Hypertension in patients with diabetes: questions
  93. Gut hormones and the brain*
  94. World Congress on the Insulin Resistance Syndrome, 2009: Cellular mechanisms of insulin resistance
  95. 2009 World Congress on the Insulin Resistance Syndrome: Cardiovascular Disease Concepts
  96. Neuropathy, Retinopathy, and Glucose-Lowering Treatments
  97. Gestational Diabetes Mellitus and Obesity
  98. Insulin treatment of Type 2 diabetes: a clinical perspective
  99. Troubling ethical questions from gestational diabetes trial
  100. Blood Pressure and Diabetic Nephropathy
  101. Incretin Concepts
  102. Hemoglobin A1cin Diabetes Diagnosis: Time for Caution
  103. Aspects of Insulin Treatment
  104. Diabetes Treatment
  105. Cardiovascular Disease in Diabetes
  106. Diabetic Retinopathy
  107. Diabetic Nephropathy
  108. Diabetic Neuropathy
  109. The Diabetic Foot
  110. The Avandia Debate
  111. Diabetic Neuropathy
  112. Cardiovascular Disease
  113. Cardiovascular Disease
  114. Gut and Adipocyte Peptides
  115. Diabetic Retinopathy and Neuropathy
  116. Diabetic Nephropathy
  117. Thiazolidinediones
  118. Insulin Resistance: Causes and Consequences
  119. Transplantation and Islet Topics
  120. Diabetes Complications
  121. Therapy of Type 2 Diabetes Mellitus
  122. Adiposity and Diabetes
  123. Diabetes and Nutrition
  124. The Epidemiology of Complications
  125. New Insights in Obesity
  126. Obesity and diabetes
  127. Antioxidants and Diabetes
  128. NIDDM Treatment
  129. Microvasculqr Function